Erasca and Bristol Myers Squibb Partner to Test ERAS-0015 Combination in Pancreatic Cancer

19 November 2026 | Thursday | News

Bristol Myers Squibb will sponsor a clinical trial evaluating Erasca’s investigational pan-RAS inhibitor ERAS-0015 in combination with navlimetostat, a PRMT5 inhibitor, in patients with MTAP-deleted pancreatic ductal adenocarcinoma. The collaboration will investigate whether targeting both RAS and PRMT5 pathways can improve treatment outcomes in this difficult-to-treat cancer.
Image Source: Public Domain

Image Source: Public Domain

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced a clinical trial collaboration and supply agreement (CTCSA) with Bristol Myers Squibb (NYSE: BMY, “BMS”) to evaluate Erasca’s potentially best-in-class pan-RAS molecular glue, ERAS-0015, with navlimetostat (BMS-986504), BMS’s investigational PRMT5 inhibitor.

Under the terms of this agreement, ERAS-0015 will be investigated in combination with navlimetostat in patients with MTAP-deleted (MTAPdel) pancreatic ductal adenocarcinoma (PDAC). BMS will sponsor the trial, and Erasca will supply ERAS-0015. The parties will retain development and commercial rights to their respective compounds, and the agreement is mutually non-exclusive.

“The early clinical activity demonstrated by ERAS-0015 has been encouraging, and we are excited to collaborate with BMS to further explore its potential in combination with navlimetostat, a clinical-stage investigational molecule with a compelling clinical profile,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “By bringing together complementary mechanisms with strong scientific rationale, this combination expands the potential of ERAS-0015 as a backbone of choice across RASm cancers and reinforces our strategy of pairing it with promising agents that may increase patient benefit. We look forward to working with BMS to advance this combination for patients with pancreatic cancer.”

Nearly all MTAP-deleted pancreatic cancers harbor co-occurring RAS mutations, creating a dependency that may make these tumors particularly susceptible to simultaneous RAS and PRMT5 inhibition. The combination of ERAS-0015 and navlimetostat may address the challenges in MTAPdel PDAC, while potentially enhancing antitumor activity.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close